Form 8-K - Current report:
SEC Accession No. 0001193125-25-027311
Filing Date
2025-02-14
Accepted
2025-02-14 16:30:19
Documents
13
Period of Report
2025-02-13
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d926272d8k.htm   iXBRL 8-K 26666
  Complete submission text file 0001193125-25-027311.txt   145175

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ttoo-20250213.xsd EX-101.SCH 2523
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ttoo-20250213_lab.xml EX-101.LAB 17203
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ttoo-20250213_pre.xml EX-101.PRE 10797
16 EXTRACTED XBRL INSTANCE DOCUMENT d926272d8k_htm.xml XML 3618
Mailing Address 101 HARTWELL AVENUE LEXINGTON MA 02421
Business Address 101 HARTWELL AVENUE LEXINGTON MA 02421 781-457-1200
T2 Biosystems, Inc. (Filer) CIK: 0001492674 (see all company filings)

EIN.: 204827488 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36571 | Film No.: 25629644
SIC: 3841 Surgical & Medical Instruments & Apparatus
(CF Office: 08 Industrial Applications and Services)